Вориконазол – новый этап в терапии системных микозов


А.В. Веселов

Увеличение распространенности тяжелых грибковых поражений и рост их рефрактерности к традиционно применяемым антимикотикам обусловливают необходимость разработки новых препаратов. Вориконазол – первый представитель антифунгальных препаратов класса азолов второго поколения. Высокая активность в отношении грибов рода Aspergillus и Candida, включая штаммы, резистентные к другим препаратам, а также Scedosporium, Fusarium и ряда других возбудителей делает возможным его применение при целом ряде клинических форм системных микозов. В проведенных рандомизированных клинических исследованиях показана достаточно высокая эффективность вориконазола при грибковых инфекциях, вызванных вышеупомянутыми патогенами. Важными положительными характеристиками вориконазола являются возможность применения ступенчатым режимом (сначала внутривенно, затем внутрь) и хороший профиль безопасности.

Литература






  1. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005;56(Suppl. 1):5–11.

  2. Singh N. Trends in epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692–96.

  3. Liebowitz LD, Ashbee HR, Evans EGV, et al. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis 2001;4:27–33.

  4. Peyron F, Favel A, Michel-Nguyen A, et al. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol 2001;39:339–42.

  5. Wouter Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004;170:621–25.

  6. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366:1013–25.

  7. Pearson MM, Rogers D, Cleary JD, et al. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003;37:420–32.

  8. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36:198–202.

  9. Marco F, Pfaller MA, Messer S, et al. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998;42:161–63.

  10. Sanati H, Belanger P, Fratti R, et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41: 2492–96.

  11. Johnston D, Zhou X, Fukuoka T, et al. Voriconazole is highly active against the 14a-demethylase of Candida krusei. Proceedings of the 39th ICAAC, San Francisco, CA, USA, 1999, abstr. 586.

  12. Belanger P, Nast CC, Fratti R, et al. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41:1840–42.

  13. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003;56(Suppl. 1):10–16.

  14. Purkins L, Wood N, Kleinermans D, et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56(Suppl. 1):17–23.

  15. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharm Ther 2003;42:395–402.

  16. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48:2166–72.

  17. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997;97:663–65.

  18. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540–47.

  19. Alkan Y, Haefeli WE, Burhenne J, et al. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration dependent adverse effect. Clin Infect Dis 2004;39: 49–52.

  20. Purkins L, Wood N, Ghahramani P, et al. Co-administration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56(Suppl. 1):37–44.

  21. Purkins L, Wood N, Kleinermans D, et al. Voriconazole potentates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56(Suppl. 1):24–29.

  22. Romero AJ, Pogamp PL, Nilsson LG, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226–34.

  23. Fortun J, Martin-Davila P, Sanchez MA, et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003;22:408–13.

  24. Tan K, Wood N, Weil A. Multiple-dose pharmacokinetics of voriconazole in chronic liver impairment. Proceedings of the 41st ICAAC, Chicago, IL, USA, 2001, abstr. 16.

  25. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:575–77.

  26. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, et al. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 1999;18:432–35.

  27. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723–27.

  28. Veselov A, Stratchounski L, Kliasova G, et al. A comparative susceptibility of Candida spp. to fluconazole and voriconazole in Russia in 2003 and 2004. Proceedings of 45th ICAAC, Washington DC, USA, 2005. Poster M-1636.

  29. Drago M, Scaltrito MM, Morace G, GISIA-2 GROUP. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004;23:619–24.

  30. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004;42:3142–46.

  31. Barchiesi F, Spreghini E, Maracci M, et al. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother 2004;48:3317–22.

  32. Hegener P, Troke PF, Tkenheuer G, et al. Treatment of fluconazole resistant candidosis with voriconazole in patients with AIDS. AIDS 1998;12:2227–41.

  33. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447–54.

  34. Troke PF, Brammer KW, Hitchcock CA, et al. UK-109,496, a novel, wide-spectrum triazole derivate for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC). Proceedings of 35th ICAAC, San Francisco, CA, USA, 1995, abstr. F73.

  35. Ostrosky-Zeichner L, Lashof A, Kullberg BJ, et al. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:651–55.

  36. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122–31.

  37. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39:743–46.

  38. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 2005;366:1435–42.

  39. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol 1998;36:2353–55.

  40. Serrano MC, Morilla D, Valverda A, et al. Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole. J Clin Microbiol 2003;41:5270–72.

  41. Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999;37:2343–45.

  42. Abraham OC, Manavathu EK, Cutright JL, et al. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis 1999;33:7–11.

  43. Manavathu EK, Abraham OC, Chandrasekar PH. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin Microbiol Infect 2001; 7:130–37.

  44. Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001;39:91–95.

  45. Vora S, Chauhan S, Brummer E, et al. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42: 2299–303.

  46. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563–71.

  47. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–15.

  48. Troke PF, Schwartz S, Ruhnke M, et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective study. Proceedings of the 43rd ICAAC, Chicago, IL, USA, 2003, abstr. M-1755.

  49. Mouas-Dupuy H, Dupont B, Lutsar I, et al. Voriconazole for bone aspergillosis: a worldwide experience of 19 cases. Proceedings of the 43rd ICAAC, Chicago, IL, USA, 2003, abstr. M-979.

  50. Steinbach WJ, Benjamin DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004;39:192–98.

  51. Patterson TF, Boucher HW, Herbrecht R, et al. European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005;41:1448–52.

  52. Lewis JS, Boucher HW, Lubowski TJ, et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacother 2005;25:839–46.

  53. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43:2163–67.

  54. van Duin D, Cleare W, Zaragoza O, et al. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48: 2014–20.

  55. Yildiran ST, Fothergill AW, Sutton DA, et al. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 2002;45:378–83.

  56. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, et al. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005;43:505–10.

  57. Miyazaki Y, Higashiyama Y, Tomono K, et al. Voriconazole treatment for pulmonary cryptococcosis. Proceedings of the 42nd ICAAC, San Francisco, CA, USA, 2002, abstr. M-882.

  58. Martin CA, Roberts S, Greenberg RN. Voriconazole treatment of disseminated paecilomyces infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2002;35:78–81.

  59. Antachopoulos C, Papakonstantinou E, Dotis J, et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J Pediatr Hematol Oncol 2005;27:283–85.

  60. Mattei D, Mordini N, Lo Nigro C, et al. Successful treatment of Acremonium fungemia with voriconazole. Mycoses 2003;46:511–14.

  61. Bigley VH, Duarte RF, Gosling RD, et al. Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. Bone Marrow Transplant 2004;34:815–17.

  62. Perfect JR, Lutsar I, Gonsales-Ruiz A. Voriconazole for the treatment of resistant and rare fungal infection. Proceedings of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans); 2000, abstr. 303.

  63. Guimera-Martin-Neda F, Garcia-Bustinduy M, Noda-Cabrera A, et al. Cutaneous infection by Fusarium: successful treatment with oral voriconazole. Br J Dermatol 2004;150:777–78.

  64. Klont RR, Eggink CA, Rijs AJ, et al. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005;40:110–12.

  65. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005;140:552–54.

  66. Garci J, Perkins A, Garau M, et al. Successful treatment with voriconazole of a Pseudoallescheria boydii fungus ball in a HIV positive patient and previous tuberculosis. Rev Iberoam Micol 2003;20:64–67.

  67. Nesky MA, McDougal EC, Peacock JE. Pseudoallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000;31:673–77.

  68. Perlroth MG, Miller J. Pseudoallescheria boydii pneumonia and empyema: a rare complication of heart transplantation cured with voriconazole. J Heart Lung Transplant 2004;23:647–49.

  69. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150:101–15.

  70. Howden BP, Slavin MA, Schwarer AP, et al. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003;22:111–13.

  71. Li RK, Ciblak MA, Nordoff N, et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000;44: 1734–36.

  72. Gonzalez GM, Fothergill AW, Sutton DA, et al. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005;43:281–84.

  73. Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin. Infect Dis 2003;36:1619-22.

  74. Prabhu RM, Bonnell M, Currier BL, et al. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004;39:74–77.

  75. Schlamm HT, Supparatpinyo K. Voriconazole as therapy for systemic infections caused by Penicillium marneffei in patients with HIV infection. Proceedings of 44th ICAAC, Washington, DC, USA, 2005, abstr. M-963-2003.

  76. Wildfeuer A, Seidl HP, Paule I, et al. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and grisefulvin. Arzeimittelforschung 1997;47:1257–63.

  77. Espinel-Ingroff A, Palacio A, Moore M. A comparison of the in vitro activity for the new triazole voriconazole with those of three established agents against dermatophytes and other molds. Proceedings of the 38th ICAAC, San Diego, CA, USA, 1998, abstr. 456.

  78. Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005;48:246–50.

  79. Ritz N, Ammann RA, Aebischer CC, et al. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr 2005;164:231–35.

  80. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–34.

  81. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273–75.

  82. Data available from www.vfend.com.

  83. Denning DW, Griffiths CE. Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001;26:648–53.

  84. Dolan CK, Hall MA, Blazes DL, et al. Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol 2004;43:768–71.

  85. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240–48.




Бионика Медиа